1029P - Cisplatin + vinorelbine treatment of recurrent or metastatic salivary gland malignancies (RMSGM): a final report on 60 cases

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anti-Cancer Agents & Biologic Therapy
Head and Neck Cancers
Presenter Oliviero Ostellino
Citation Annals of Oncology (2014) 25 (suppl_4): iv340-iv356. 10.1093/annonc/mdu340
Authors O. Ostellino1, M. Garzaro2, F. Pedani1, M. Airoldi1, E. Bellini1, L. Raimondo2, G. Pecorari2
  • 1Sc Oncologia 2, Città della Saluta e della Scienza - Torino, 10128 - Torino/IT
  • 2Surgical Sciences Department, 1st ENT Division - University of Turin, 10126 - Turin/IT

Abstract

Aim

RMSGM are not suitable for conventional treatment. We report the clinical outcomes of 60 patients affected by RMSGM who were treated with DDP + VNB as a first- or second-line scheme.

Methods

Sixty patients between 2001 and 2008, affected by RMSGM were enrolled in this cohort prospective study; they received the following first- or second-line CT, for a maximum of 6 cycles: DDP at 80 mg/m2 on d 1 + VNB at 25 mg/ m2 on d 1 and 8, at 3-wk intervals.

Results

Seventy percent of the patients received DDP + VNB as the first-line CT and 30% of them received it as the second-line CT. After 5 cycles (median) of first-line DDP + VNB, 7% of the patients achieved a CR, 24% achieved a PR, 33% achieved an NC and 36% achieved a PD. After 4 cycles (median) of second-line CT, 0 patients achieved a CR, 5% achieved a PR, 33% achieved an NC and 62% achieved a PD. The median OS period was 10 months for those who received the first-line CT and 4 months for those who received the second-line CT. The best ORR (54%) and median survival were observed, during first line treatment, in adenocarcinomas, whereas undifferentiated tumours were unresponsive with a poor median survival (4.6 months).

Conclusions

Adenocarcinomas show the best response and prognosis with DDP + VNB scheme that seems to be an effective and well-tolerated first-line CT for RMSGM, whereas it has only low palliative activity as a second-line CT.

Disclosure

All authors have declared no conflicts of interest.